China Cord Blood Corp (CO)

[steeledge]

They ended up getting full over-allotment; that's somewhat encouraging.

China Cord Blood Corporation Announces Full Exercise of Over-Allotment Option

HONG KONG, Jan. 1 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the underwriters of its recent public offering of common stock have exercised the remaining portion of their over-allotment option, which will result in the issuance of an additional 181,000 ordinary shares. The option was granted in connection with the public offering of 3,305,786 ordinary shares at a public offering price of $6.05 per share, which closed on November 24, 2009. The closing of the full over-allotment issuance of 495,867 ordinary shares is scheduled for Tuesday, January 5, 2010 and will bring the total gross proceeds of the public offering to $23 million. China Cord Blood Corporation intends to use the net proceeds from the offering for the expansion into new geographical markets, including applications for new licenses and acquisitions and investments, and for the construction and upgrading of facilities in existing geographical markets.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) acted as lead Manager of the offering and Macquarie Capital acted as co-manager for the offering.